Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $12.4 million.

  • AtriCure's Share-based Compensation rose 1987.65% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.8 million, marking a year-over-year increase of 1138.51%. This contributed to the annual value of $40.4 million for FY2024, which is 1309.06% up from last year.
  • Latest data reveals that AtriCure reported Share-based Compensation of $12.4 million as of Q3 2025, which was up 1987.65% from $11.4 million recorded in Q2 2025.
  • AtriCure's Share-based Compensation's 5-year high stood at $12.4 million during Q3 2025, with a 5-year trough of $6.6 million in Q1 2021.
  • Over the past 5 years, AtriCure's median Share-based Compensation value was $8.8 million (recorded in 2023), while the average stood at $8.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 5063.87% in 2021, then tumbled by 453.64% in 2022.
  • Quarter analysis of 5 years shows AtriCure's Share-based Compensation stood at $7.5 million in 2021, then decreased by 4.54% to $7.2 million in 2022, then rose by 29.39% to $9.3 million in 2023, then rose by 11.52% to $10.4 million in 2024, then increased by 19.63% to $12.4 million in 2025.
  • Its last three reported values are $12.4 million in Q3 2025, $11.4 million for Q2 2025, and $9.6 million during Q1 2025.